New Analysis Explains What Lilly’s ObesityWeek 2026 EloraTZP Results Add to the September Phase 2b Readout and What They Leave Unchanged

Nov 17, 2026

Eloralintide-Peptide.com Breaks Down Lilly's ObesityWeek 2026 EloraTZP Data and the First Participant-Reported Findings on Eloralintide. New analysis separates what changed at ObesityWeek from what did not: responder rates and exit-interview data are new, the headline weight-loss figures are not.

Los Angeles, United States, November 17, 2026 -- Los Angeles, CA – Eloralintide Peptide Research, an independent research resource covering the investigational amylin receptor agonist eloralintide, has published a plain-language breakdown of the data Eli Lilly presented at ObesityWeek 2026 in Washington, DC. The full analysis is available at https://eloralintide-peptide.com/eloralintide-obesityweek-2026/.

Lilly's presentations covered two sets of findings. The first was a group of new responder analyses from the 48-week Phase 2b trial of EloraTZP, the combination of eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes (NCT06603571). The second was the first patient-experience data from the eloralintide Phase 2 monotherapy trial (NCT06230523).

What the new analyses reported

  • Up to 60% of participants on the combination no longer met BMI criteria for obesity at 48 weeks.
  • Up to 77% reached normal blood sugar levels, with A1C falling by as much as 2.9 points.
  • In exit interviews from the monotherapy trial, 74% of eloralintide participants reported fewer food cravings and 52% reported less "food noise."
  • Among participants who drank alcohol at baseline, 41% reported drinking less.

What did not change

The analysis stresses that ObesityWeek produced no new average weight-loss results. The headline figures still come from the September 30, 2026 readout at EASD: 23.3% mean weight loss with eloralintide 9 mg plus tirzepatide 15 mg, against 14.8% with tirzepatide 15 mg alone.

It also flags the limits of the new material. The exit-interview findings are qualitative and self-reported, not trial endpoints. Tolerability remains the open question: 10.8% to 27.0% of participants on the combinations stopped treatment because of side effects, compared with 2.9% on tirzepatide alone. Lilly's Phase 3 program uses a single-injection co-formulation with a slower escalation schedule, and whether that lowers discontinuations will not be known until those trials read out.

"Responder rates make strong headlines, but they are a different cut of the same September data, not a new result," said the editorial team at Eloralintide-Peptide.com. "Our job is to show readers which numbers are new, which are self-reported, and which questions only Phase 3 can answer."

Neither eloralintide nor EloraTZP is approved by the FDA or any other regulator. The site will continue to track the program, including updates analysts expect at Lilly's Innovation Day on December 7, 2026.

Read more articles on eloralintide research, trial data and sourcing, including a look at how the compound is being discussed on reddit.

About Eloralintide Peptide Research

Eloralintide Peptide Research is an independent research resource focused on a single compound. It covers published clinical trials, sourcing checks and certificates of analysis, with figures linked to their original sources. The site is not affiliated with Eli Lilly and Company.

Disclaimer: Content is for research and informational purposes only and is not medical advice. Eloralintide is an investigational compound that has not been approved by the FDA or any other regulator. Clinical trial results describe the investigational drug studied and are not evidence about any vendor's product.

Contact Info:
Name: Benson Jamison
Email: Send Email
Organization: Eloralintide Peptide Research
Phone: 3105613389
Website: https://eloralintide-peptide.com/

Release ID: 89209868

In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.

MORE NEWS
Suresh Raina's Message to Young Cricketers: Perform in UP to Earn IPL Contracts | Rising Bharat
Nov 17, 2026
Suresh Raina's Message to Young Cricketers: Perform in UP to Earn IPL Contracts | Rising Bharat

Former India cricketer Suresh Raina has a clear message for young cricketers chasing their IPL dreams: perform at the domestic level first! Recalling his conversations with emerging players, Raina says he reminded them that strong performances for Uttar Pradesh are important if they want to earn opportunities and IPL contracts.In this candid conversation, Raina reflects on the importance of domestic cricket as a foundation for professional success. From proving yourself in state-level tournaments to attracting the attention of IPL franchises, his message is that talent alone is not enough — consistency and performances matter.Raina also opens up about a more personal side of his life, sharing the stories and memories behind his tattoos. What do the tattoos represent? What inspired him to get them? And what lessons from his own cricketing journey does he want the next generation to take away?Known for his contribution to India's 2011 World Cup-winning campaign and his memorable IPL career, Raina has also spoken about how domestic cricket shaped his development as a player. Watch this special conversation for Suresh Raina's take on UP cricket, IPL opportunities, the importance of performing at the grassroots level and the stories behind his tattoos. CNN-News18 is your trusted source for breaking news, updates, and in-depth analysis from around the world. CNN-News18 is dedicated to bringing you the latest news, trends, and insights, helping you stay informed and up-to-date. Subscribe Now and join our community of informed and engaged viewers. Follow Every Breaking Story LIVE Watch News18 LIVE 24x7: https://youtube.com/live/rfDx1HMvXbQFollow us on Google: news18.co/cn18gFollow CNN News18 on X: https://x.com/CNNnews18Follow CNN News18 on Instagram: https://www.instagram.com/cnnnews18/Follow CNN News18 on Facebook: facebook.com/cnnnews18 with latest headlines on politics, sports and entertainment on news18.comNews18 Mobile App - https://onelink.to/desc-youtube

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

About Us

Recent Discovery will take you to the captivating developments in science, technology, and the universe around us. We deliver to you the latest news, theories, and developments in the world of science.

Copyright © 2015 - 2026 Recent Discovery. All Rights Reserved.